title: [Clinical efficacy of lauromacrogol combined with pingyangmycin in the treatment of venous malformation: clinical analysis of 120 consecutive cases].
abstract: OBJECTIVE
  To compare the clinical efficacy of pingyangmycin and lauromacrogol combined with pingyangmycin in the treatment of venous malformations (VMs).
  
  
  METHODS
  One hundred and twenty patients with VM were randomly divided into lauromacrogol combined with pingyangmycin injection group (experimental group) and pingyangmycin injection group (control group). The appropriate interval between different injection sessions was 2 weeks. After different sessions, the changes of lesions (including size, color, texture) as well as the results of posture test and adverse effects were analyzed by using SPSS11.5 software package.
  
  
  RESULTS
  According to the international evaluation criteria for VM, the efficacy of the experimental group was significantly better than the control group after 2~5 sessions (P<0.05). However, after 1 and 6 sessions, there was no significant difference in the efficacy between the experimental group and the control group (P>0.05). In addition, the average sessions required in the experimental group were significantly less than those in the control group (P<0.05).
  
  
  CONCLUSIONS
  Compared to the single use of pingyangmycin, lauromacrogol combined with pingyangmycin is more effective for the treatment of VM, with fewer sessions required and no adverse effects.
authors.affiliation: Department of Stomatology, Gezhouba Central Hospital, Third Clinical College, Three Gorge University. Yichang 443002, China E-mail:1695194772@qq.com.
authors.forename: Li
authors.initials: L
authors.lastname: Liu
authors.forename: Dong-Xiao
authors.initials: DX
authors.lastname: Liu
authors.forename: Ji-Hong
authors.initials: JH
authors.lastname: Zhao
authors.forename: Yu
authors.initials: Y
authors.lastname: Cai
authors.forename: Hao-Yan
authors.initials: HY
authors.lastname: Zhong
mesh_terms: D001761:Bleomycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003116:Color; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011187:Posture; D015911:Sclerotherapy; D016896:Treatment Outcome; D054079:Vascular Malformations / Q000188:drug therapy*; D014680:Veins
chemical_list: D000077423:Polidocanol; D001761:Bleomycin; D011092:Polyethylene Glycols; C025703:bleomycetin